Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
CA 2105071 C · Owner: Kem, William R. · Inventors: Meyer, Edwin M.; Kem, William R.; Zoltewicz, John A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel pharmaceutical composition for use as an anti-neurodegenerative agent, comprising anabaseine, DMAB-anabaseine or anabasine in combination with a, pharmaceutically acceptable carrier the anabaseine having the general , chemical structure: (see formula I), and the anabaseine, DMAB-anabaseine or anabasine also known by the following respective, chemical formulae: 2-(3-pyridyl)-3,4,5,6-tetrahydropyridine 3-p-, (dimethylamino), benzylidene-3,4,5,6-tetrahydro-2,3'-bypyridine and 2-(3-pyridyl) piperidine. , A novel method of making an anabaseine-based pharmaceutical composition is also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 27, 1992 and granted May 14, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 27, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 27, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.